Vyriad
Announced 23 Dec 2025$85.0M · Series B · Hospitals and Health Care · United States
At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells.
“A biotech born in Minnesota taking aim at cancer’s chaos, it’s the kind of ambition that doesn’t announce itself. Vyriad isn’t chasing headlines, it’s engineering history. The Rochester-based company just closed a $25 million final tranche of its Series B, bringing the round to $85 million and total funding beyond $100 million.”
11 more sources tracked. Read the full press release and reporter coverage.
Sign up to read →Investors: Harry Stine of Stine Seed Company Farms, Mayo Clinic, Regeneron Pharmaceuticals, Mirae Asset Global Investments, Southeast Minnesota Capital Fund LLC.
